OBJECTIVE: To assess and compare direct medical costs (incurred by payers) and indirect productivity losses (incurred by employers) associated with influenza seasons with matched or mismatched circulating and vaccine containing influenza B lineages. METHODS: A retrospective analysis, using two MarketScan databases, for the years 2000-2009. Each influenza season was categorized as matched or mismatched after comparing that season's circulating influenza B lineage and the vaccine influenza B lineage. Patients selected had at least one diagnosis claim for influenza (ICD-9-CM code 487.xx [influenza] or 488.1 [H1N1]) during an influenza season. We assessed the incidence of influenza (overall and influenza B), influenza-related medical utilization and associated costs, and productivity losses for each season. RESULTS: The four matched seasons had lower average influenza incidence (overall incidence per 100,000 plan members: 509; 95% confidence interval [CI]: 505-512) than the five mismatched seasons (748; 95% CI: 745-751). The mismatched seasons had lower influenza B incidence (average incidence per 100,000 plan members: 126; 95% CI: 125-128) than the matched seasons (165; 95% CI: 163-167). The average, per-patient, total influenza-related medical costs in the mismatched seasons ($300.83; range: $245.38-$371.58) were approximately $61.00 higher than in the matched seasons ($239.43; range: $201.49-$264.01). The mismatched seasons had greater average per-patient, influenza-related productivity-loss costs than the matched seasons (mean: $237.31 vs. $175.10). CONCLUSION: CDC data showed that influenza A was the predominant circulating strain during seasons in which the circulating influenza B lineage did not match the vaccine influenza B lineage. This resulted in lower influenza B incidence during the mismatched seasons. However, the average, per-patient, influenza-related direct medical costs and indirect productivity losses were higher during the mismatched seasons. Additional research is required to determine if these higher costs can be attributed to influenza B infections and if the influenza severity varies during mismatched seasons.
OBJECTIVE: To assess and compare direct medical costs (incurred by payers) and indirect productivity losses (incurred by employers) associated with influenza seasons with matched or mismatched circulating and vaccine containing influenza B lineages. METHODS: A retrospective analysis, using two MarketScan databases, for the years 2000-2009. Each influenza season was categorized as matched or mismatched after comparing that season's circulating influenza B lineage and the vaccine influenza B lineage. Patients selected had at least one diagnosis claim for influenza (ICD-9-CM code 487.xx [influenza] or 488.1 [H1N1]) during an influenza season. We assessed the incidence of influenza (overall and influenza B), influenza-related medical utilization and associated costs, and productivity losses for each season. RESULTS: The four matched seasons had lower average influenza incidence (overall incidence per 100,000 plan members: 509; 95% confidence interval [CI]: 505-512) than the five mismatched seasons (748; 95% CI: 745-751). The mismatched seasons had lower influenza B incidence (average incidence per 100,000 plan members: 126; 95% CI: 125-128) than the matched seasons (165; 95% CI: 163-167). The average, per-patient, total influenza-related medical costs in the mismatched seasons ($300.83; range: $245.38-$371.58) were approximately $61.00 higher than in the matched seasons ($239.43; range: $201.49-$264.01). The mismatched seasons had greater average per-patient, influenza-related productivity-loss costs than the matched seasons (mean: $237.31 vs. $175.10). CONCLUSION: CDC data showed that influenza A was the predominant circulating strain during seasons in which the circulating influenza B lineage did not match the vaccine influenza B lineage. This resulted in lower influenza B incidence during the mismatched seasons. However, the average, per-patient, influenza-related direct medical costs and indirect productivity losses were higher during the mismatched seasons. Additional research is required to determine if these higher costs can be attributed to influenza B infections and if the influenza severity varies during mismatched seasons.
Keywords:
CCAE; CDC; CI; Centers for Disease Control and Prevention; Commercial Claims and Encounters; HPM; Health and Productivity Management; Health care cost; ICD-9-CM; International Classification of Diseases, Ninth Revision, Clinical Modification; NREVSS; National Respiratory and Enteric Virus Surveillance System; Productivity loss; Strain mismatch; US; United States; WHO; World Health Organization.; confidence interval
Authors: Edward W Thommes; Morgan Kruse; Michele Kohli; Rohita Sharma; Stephen G Noorduyn Journal: Hum Vaccin Immunother Date: 2016-11-18 Impact factor: 3.452
Authors: Caroline de Courville; Sarah M Cadarette; Erika Wissinger; Fabián P Alvarez Journal: Influenza Other Respir Viruses Date: 2022-02-05 Impact factor: 4.380
Authors: Saverio Caini; Q Sue Huang; Meral A Ciblak; Gabriela Kusznierz; Rhonda Owen; Sonam Wangchuk; Cláudio M P Henriques; Richard Njouom; Rodrigo A Fasce; Hongjie Yu; Luzhao Feng; Maria Zambon; Alexey W Clara; Herman Kosasih; Simona Puzelli; Herve A Kadjo; Gideon Emukule; Jean-Michel Heraud; Li Wei Ang; Marietjie Venter; Alla Mironenko; Lynnette Brammer; Le Thi Quynh Mai; François Schellevis; Stanley Plotkin; John Paget Journal: Influenza Other Respir Viruses Date: 2015-08 Impact factor: 4.380
Authors: Anne Mosnier; Saverio Caini; Isabelle Daviaud; Jean-Louis Bensoussan; Françoise Stoll-Keller; Tan Tai Bui; Bruno Lina; Sylvie Van der Werf; Jean Marie Cohen Journal: BMC Infect Dis Date: 2015-08-21 Impact factor: 3.090